ACLM Board Review Quiz: Clinical Pro
fn fn fn fn fn
cesses in Lifestyle Medicine (Section 3
fn fn fn fn fn
)
AccordingfntofnthefnAmericanfnDiabetesfnAssociationfnnationalfnguidelines,fnwhenfncanfnthefn
diagnosisfnoffnprediabetesfnbefnmade?
a.fnTwofnseparatefnfastingfnbloodfnglucosefnreadingsfnlessfnthanfn80-90fnmg/dLfn(4.4-
5.0fnmmol/L)
b.fnAfnsinglefnfastingfnbloodfnglucosefnreadingfninfnthefnrangefnoffn100-125fnmg/dLfn(5.6-
6.9fnmmol/L)
c.fnAnfnoralfnglucosefntolerancefntestfn(OGTT)fnwithfnafnbloodfnglucosefnreadingfnoffn≥fn200fn
mg/dLfn(11.1fnmmol/L)
d.fnAfnsinglefnrandomfnbloodfnglucosefnreadingfnoffn≥fn200fnmg/dLfn(11.1fnmmol/L)fnwithoutfna
nyfnconcerningfnsymptomsfnoffndiabetesfn(hyperglycemicfncrisis)fn-fncorrectfnanswer✔ ✔
b.fnAfnsinglefnfastingfnbloodfnglucosefnreadingfninfnthefnrangefnoffn100-125fnmg/dLfn(5.6-
6.9fnmmol/L)
Whichfnoffnthefnfollowingfndescribesfnanfnoptimalfnlifestylefnmedicinefntreatmentfnplanfnforfnpr
ediabetes?
a.fnPrescriptionfnforfnphysicalfnactivityfnoffn90fnminutesfnperfnweekfnandfnmetforminfn850fnmgf
twicefndaily.
n
b.fnPrescriptionfnforfnthefnAmericanfnDiabetesfnAssociationfn(ADA)fndietfnandfnmetforminfn85
0fnmgfntwicefndaily.
, c.fnPrescriptionfnforfnafnweight-
lossfnprogramfnandfnregularfnexercisefnwithfnthefngoalsfnoffnlosingfn7%fnoffninitialfnbodyfnweig
htfnandfnexercisingfn150fnminutesfnperfnweek.
d.fnNofnimmediatefnprescriptionfnisfnnecessary;fnhowever,fnthefnconditionfnshouldfnbefnmonit
oredfneveryfn6fnmonthsfnwithfnlabfnworkfn(fastingfnglucosefnandfnHbA1c).fn-fncorrectfnanswer
✔ ✔ c.fnPrescriptionfnforfnafnweight-
lossfnprogramfnandfnregularfnexercisefnwithfnthefngoalsfnoffnlosingfn7%fnoffninitialfnbodyfnweig
htfnandfnexercisingfn150fnminutesfnperfnweek.
Whichfnoffnthefnfollowingfninitialfnweight-
lossfngoalsfnforfnafnpatientfnwithfnafnBMIfnoffn27fnisfntypicallyfnrecommended?
a.fn0-4%fnoffnbodyfnweight
b.fn5-10%fnoffnbodyfnweight
c.fn11-15%fnoffnbodyfnweight
d.fnThisfnpatientfnhasfnafnnormalfnBMIfnandfndoesfnnotfnneedfntofnlosefnweight.fn-
correctfnanswer✔ ✔ b.fn5-10%fnoffnbodyfnweight
fn
Anfnofficefnusesfnanfn(EMR)fnplatformfnthatfnhasfnthefnfunctionalityfntofnidentifyfnpopulationsfn
offnpatientsfnwithfnthefnsamefndiagnosisfncode.fnHowfncouldfnthisfnbefnusedfntofnmonitorfnthefni
mpactfnoffnlifestylefnmedicinefntreatments?
a.fnThefnEMRfncouldfnidentifyfnallfnpatientsfnwithfnthefndiagnosisfncodefnoffn"T2DM"fnandfnafnc
onditionfnmanagementfnnursefncouldfnreviewfnchartfnreportsfntofnensurefnthey'vefneachfnhadf
a monofilamentfntestfnandfneyefnexamfninfnthefnpastfnyear.
n fn
b.fnPatientsfnwithfnthefndiagnosisfnoffn"heartfnfailure"fncouldfnbefnidentified.fnAfnreviewfncouldfn
helpfnensurefnappropriatefnprescriptionsfnandfnthatfnroutinelyfnfillingfnforfnanfnACE-
inhibitorfnhavefnbeenfncompleted.
c.fnAfndiagnosisfncodefnforfn"dietaryfncounselingfnandfnsurveillance"fncouldfnbefnchartedfneac
hfntimefnafnproviderfngavefnweight-
lossfnadvice.fnThesefnchartsfncouldfnbefnanalyzedfnforfnweightfnlossfnoverfntime.
fn fn fn fn fn
cesses in Lifestyle Medicine (Section 3
fn fn fn fn fn
)
AccordingfntofnthefnAmericanfnDiabetesfnAssociationfnnationalfnguidelines,fnwhenfncanfnthefn
diagnosisfnoffnprediabetesfnbefnmade?
a.fnTwofnseparatefnfastingfnbloodfnglucosefnreadingsfnlessfnthanfn80-90fnmg/dLfn(4.4-
5.0fnmmol/L)
b.fnAfnsinglefnfastingfnbloodfnglucosefnreadingfninfnthefnrangefnoffn100-125fnmg/dLfn(5.6-
6.9fnmmol/L)
c.fnAnfnoralfnglucosefntolerancefntestfn(OGTT)fnwithfnafnbloodfnglucosefnreadingfnoffn≥fn200fn
mg/dLfn(11.1fnmmol/L)
d.fnAfnsinglefnrandomfnbloodfnglucosefnreadingfnoffn≥fn200fnmg/dLfn(11.1fnmmol/L)fnwithoutfna
nyfnconcerningfnsymptomsfnoffndiabetesfn(hyperglycemicfncrisis)fn-fncorrectfnanswer✔ ✔
b.fnAfnsinglefnfastingfnbloodfnglucosefnreadingfninfnthefnrangefnoffn100-125fnmg/dLfn(5.6-
6.9fnmmol/L)
Whichfnoffnthefnfollowingfndescribesfnanfnoptimalfnlifestylefnmedicinefntreatmentfnplanfnforfnpr
ediabetes?
a.fnPrescriptionfnforfnphysicalfnactivityfnoffn90fnminutesfnperfnweekfnandfnmetforminfn850fnmgf
twicefndaily.
n
b.fnPrescriptionfnforfnthefnAmericanfnDiabetesfnAssociationfn(ADA)fndietfnandfnmetforminfn85
0fnmgfntwicefndaily.
, c.fnPrescriptionfnforfnafnweight-
lossfnprogramfnandfnregularfnexercisefnwithfnthefngoalsfnoffnlosingfn7%fnoffninitialfnbodyfnweig
htfnandfnexercisingfn150fnminutesfnperfnweek.
d.fnNofnimmediatefnprescriptionfnisfnnecessary;fnhowever,fnthefnconditionfnshouldfnbefnmonit
oredfneveryfn6fnmonthsfnwithfnlabfnworkfn(fastingfnglucosefnandfnHbA1c).fn-fncorrectfnanswer
✔ ✔ c.fnPrescriptionfnforfnafnweight-
lossfnprogramfnandfnregularfnexercisefnwithfnthefngoalsfnoffnlosingfn7%fnoffninitialfnbodyfnweig
htfnandfnexercisingfn150fnminutesfnperfnweek.
Whichfnoffnthefnfollowingfninitialfnweight-
lossfngoalsfnforfnafnpatientfnwithfnafnBMIfnoffn27fnisfntypicallyfnrecommended?
a.fn0-4%fnoffnbodyfnweight
b.fn5-10%fnoffnbodyfnweight
c.fn11-15%fnoffnbodyfnweight
d.fnThisfnpatientfnhasfnafnnormalfnBMIfnandfndoesfnnotfnneedfntofnlosefnweight.fn-
correctfnanswer✔ ✔ b.fn5-10%fnoffnbodyfnweight
fn
Anfnofficefnusesfnanfn(EMR)fnplatformfnthatfnhasfnthefnfunctionalityfntofnidentifyfnpopulationsfn
offnpatientsfnwithfnthefnsamefndiagnosisfncode.fnHowfncouldfnthisfnbefnusedfntofnmonitorfnthefni
mpactfnoffnlifestylefnmedicinefntreatments?
a.fnThefnEMRfncouldfnidentifyfnallfnpatientsfnwithfnthefndiagnosisfncodefnoffn"T2DM"fnandfnafnc
onditionfnmanagementfnnursefncouldfnreviewfnchartfnreportsfntofnensurefnthey'vefneachfnhadf
a monofilamentfntestfnandfneyefnexamfninfnthefnpastfnyear.
n fn
b.fnPatientsfnwithfnthefndiagnosisfnoffn"heartfnfailure"fncouldfnbefnidentified.fnAfnreviewfncouldfn
helpfnensurefnappropriatefnprescriptionsfnandfnthatfnroutinelyfnfillingfnforfnanfnACE-
inhibitorfnhavefnbeenfncompleted.
c.fnAfndiagnosisfncodefnforfn"dietaryfncounselingfnandfnsurveillance"fncouldfnbefnchartedfneac
hfntimefnafnproviderfngavefnweight-
lossfnadvice.fnThesefnchartsfncouldfnbefnanalyzedfnforfnweightfnlossfnoverfntime.
